Related Experiment Video
Updated: May 18, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Prognostic value of miR-29a expression in pediatric acute myeloid leukemia
Conglong Zhu1, Yeguo Wang, Wenxia Kuai
1Department of Pediatrics, Huai'an First People's Hospital, Nanjing Medical University, 6 Beijing Road West, Huai'an, Jiangsu 223300, PR China.
Objectives:
As a member of miR-29 family, miR-29a can act as either oncogene or tumor suppressor. However, its expression patterns in acute myeloid leukemia (AML) are controversial according to previous studies. Thus, the aim of this study was to determine the expression and clinical significance of miR-29a in pediatric AML.
Methods:
Expression levels of miR-29a in bone marrow mononuclear cells were detected by real-time quantitative PCR in a cohort of 106 patients with newly diagnosed pediatric AML. The prognostic values of miR-29a in pediatric AML were also analyzed.
Results:
Compared with normal controls, we demonstrated a significantly decreased expression of miR-29a in the bone marrow of pediatric AML patients (P<0.001). The expression levels of miR-29a were significantly lower in French-American-British classification subtype M7 than in other subtypes (P<0.001) and differed significantly across cytogenetic risk groups (P=0.002) with high miR-29a expression among those with favorable karyotypes. Moreover, low miR-29a expression was significantly associated with shorter relapse-free (P<0.001) and overall (P=0.008) survival in pediatric AML patients. Cox proportional hazards multivariate analysis of the univariate predictors identified cytogenetic risk and miR-29a expression as independent prognostic factors for relapse-free survival and overall survival. More interestingly, the prognostic value of miR-29a expression was more obvious in the subgroup of patients with intermediate-risk cytogenetics.
Conclusion:
Our data indicate for the first time that the down-regulation of miR-29a was associated with advanced clinical features and poor prognosis of pediatric AML patients, suggesting that miR-29a down-regulation may be used as an unfavorable prognostic marker in pediatric AML.
Insights
Down-regulation of miR-29a is linked to poor prognosis in pediatric acute myeloid leukemia (AML). Low miR-29a expression indicates advanced disease and shorter survival, suggesting its potential as an unfavorable prognostic marker in pediatric AML.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- MicroRNA-29a (miR-29a), part of the miR-29 family, has a dual role as an oncogene or tumor suppressor.
- Previous studies show conflicting expression patterns of miR-29a in acute myeloid leukemia (AML).
Purpose of the Study:
- To investigate the expression levels of miR-29a in pediatric AML.
- To determine the clinical significance and prognostic value of miR-29a in pediatric AML.
Main Methods:
- Real-time quantitative PCR was used to measure miR-29a expression in bone marrow mononuclear cells from 106 newly diagnosed pediatric AML patients.
- Statistical analyses, including Cox proportional hazards multivariate analysis, were performed to assess prognostic values.
Main Results:
- Pediatric AML patients exhibited significantly decreased miR-29a expression compared to normal controls.
- Lower miR-29a levels were observed in FAB M7 subtype and were associated with adverse cytogenetic risk groups.
- Low miR-29a expression correlated with shorter relapse-free and overall survival, identified as an independent prognostic factor.
Conclusions:
- Down-regulation of miR-29a is associated with advanced clinical features and poor prognosis in pediatric AML.
- miR-29a down-regulation serves as a potential unfavorable prognostic marker for pediatric AML.
- The prognostic value of miR-29a is particularly evident in intermediate-risk cytogenetics subgroups.
